Alnylam’s Shares Surge on Institutional Interest as $360M Volume Ranks 309th in U.S. Markets

On October 7, 2025, Alnylam Pharmaceuticals (ALNY) closed with a 1.68% gain, with a trading volume of $360 million, ranking 309th in volume among U.S.-listed stocks. The biotech firm's shares saw renewed institutional interest following updated clinical data from its Givosiran pipeline, which demonstrated sustained efficacy in treating acute hepatic porphyria. Analysts highlighted the compound's potential to secure broader label approvals in 2026, though noted near-term risks from upcoming Phase III competitor trials.

Short-term technical indicators showed mixed signals, with RSI crossing above 50 while MACD remained in bearish territory. Institutional ownership data revealed a 12% increase in average daily buy orders from asset managers, contrasting with a 7% drop in retail participation. The biotech sector's overall weakness limited upside momentum, as broader market indices closed flat amid mixed macroeconomic data.

Backtesting of a volume-weighted cross-sectional strategy for U.S. equities faces current technical constraints. Implementation requires full-universe turnover data for daily ranking of top 500 stocks, which exceeds available tools' capacity to handle multi-asset rebalancing. Alternative approaches include testing via high-volume ETF proxies or narrow-scope single-asset tests. Custom scripting remains the only viable path for full implementation of the proposed strategy.